LTX-568 is a small-molecule new drug, a potent and safe 5-HT7R antagonist. The starting meterials are easy to obtain. Moreover, our API requires only five steps of standard chemical synthesis, indicating that this protocol has strong potential for scalable manufacturing. Recently, we completed Chemistry, Manufacturing, and Controls). The dosing frequency will design as once daily via oral adminstration, hoping to reduce the inconvenience of patients.
LTX-568 has undergone three rounds of optimization.
- Higher affinity：Ki<10 nM, increasing LTX-568’s potency.
- Higher selectivity：>100-fold of >160 other protein targets.
- Higher solubility：water solubility >10 mg/mL
- Higher tissue selectivity：Accroding to animal experiments, LTX-568 has tissue selectivity.
- Higher safty：Accroding to animal repeat-toxicity study of rat and dog, the data showed LTX-568 is very safe.
- Stronger analgesic effect：LTX-568 have strong analgesic effect in two different types of IBS-related mouse model,and don’t affect normal intestinal physiology.